• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿齐沙坦对昼夜血压变异性的改善作用。

Improvement of Diurnal Blood Pressure Variation by Azilsartan.

作者信息

Okamura Keisuke, Shirai Kazuyuki, Okuda Tetsu, Urata Hidenori

机构信息

Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Chikushino, Japan.

出版信息

J Clin Med Res. 2018 Jan;10(1):41-49. doi: 10.14740/jocmr3228w. Epub 2017 Dec 1.

DOI:10.14740/jocmr3228w
PMID:29238433
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5722044/
Abstract

BACKGROUND

Azilsartan is an angiotensin II receptor blocker with a potent antihypertensive effect.

METHODS

In a multicenter, prospective, open-label study, 265 patients with poor blood pressure control despite treatment with other angiotensin II receptor blockers were switched to 20 mg/day of azilsartan (patients on standard dosages) or 40 mg/day of azilsartan (patients on high dosages).

RESULTS

Blood pressure was 149/83 mm Hg before switching and was significantly reduced from 1 month after switching until final assessment (132/76 mm Hg, P < 0.001). The pulse rate was 72/min before switching and increased significantly from 3 months after switching until final assessment (74/min, P < 0.005). A significant decrease of home morning systolic and diastolic pressure was observed from 1 and 3 months, respectively. Home morning blood pressure was 143/82 mm Hg before switching and 130/76 mm Hg at final assessment (P < 0.01). The morning-evening difference of systolic blood pressure decreased from 14.6 to 6.6 mm Hg after switching (P = 0.09). The estimated glomerular filtration rate was significantly decreased at 3, 6, and 12 months after switching, and serum uric acid was significantly increased at 12 months. No serious adverse events occurred.

CONCLUSION

Azilsartan significantly reduced the blood pressure and decreased diurnal variation in patients responding poorly to other angiotensin II receptor blockers.

摘要

背景

阿齐沙坦是一种具有强效降压作用的血管紧张素II受体阻滞剂。

方法

在一项多中心、前瞻性、开放标签研究中,265例尽管使用其他血管紧张素II受体阻滞剂治疗但血压控制不佳的患者,被换用阿齐沙坦20毫克/天(标准剂量患者)或40毫克/天(高剂量患者)。

结果

换药前血压为149/83毫米汞柱,换药后1个月至最终评估时显著降低(132/76毫米汞柱,P<0.001)。换药前脉搏率为72次/分钟,换药后3个月至最终评估时显著升高(74次/分钟,P<0.005)。分别在换药后1个月和3个月观察到家庭晨起收缩压和舒张压显著下降。换药前家庭晨起血压为143/82毫米汞柱,最终评估时为130/76毫米汞柱(P<0.01)。换药后收缩压的早晚差值从14.6毫米汞柱降至6.6毫米汞柱(P=0.09)。换药后3、6和12个月时估计肾小球滤过率显著降低,12个月时血清尿酸显著升高。未发生严重不良事件。

结论

阿齐沙坦可显著降低对其他血管紧张素II受体阻滞剂反应不佳患者的血压,并减少昼夜血压变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/cbf69274dd9c/jocmr-10-041-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/785c40fe8637/jocmr-10-041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/934d96b31803/jocmr-10-041-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/cbf69274dd9c/jocmr-10-041-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/785c40fe8637/jocmr-10-041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/934d96b31803/jocmr-10-041-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/522b/5722044/cbf69274dd9c/jocmr-10-041-g003.jpg

相似文献

1
Improvement of Diurnal Blood Pressure Variation by Azilsartan.阿齐沙坦对昼夜血压变异性的改善作用。
J Clin Med Res. 2018 Jan;10(1):41-49. doi: 10.14740/jocmr3228w. Epub 2017 Dec 1.
2
Effect of Azilsartan on Day-to-Day Variability in Home Blood Pressure: A Prospective Multicenter Clinical Trial.阿齐沙坦对家庭血压每日变异性的影响:一项前瞻性多中心临床试验
J Clin Med Res. 2017 Jul;9(7):618-623. doi: 10.14740/jocmr3050w. Epub 2017 May 22.
3
Effects of azilsartan compared to other angiotensin receptor blockers on left ventricular hypertrophy and the sympathetic nervous system in hemodialysis patients.与其他血管紧张素受体阻滞剂相比,阿齐沙坦对血液透析患者左心室肥厚和交感神经系统的影响。
Ther Apher Dial. 2014 Oct;18(5):398-403. doi: 10.1111/1744-9987.12168. Epub 2014 Feb 25.
4
Examination of the effect of changing to azilsartan from candesartan in renal transplant patients.肾移植患者从坎地沙坦换用阿齐沙坦的效果研究。
Transplant Proc. 2014;46(2):492-5. doi: 10.1016/j.transproceed.2013.11.018.
5
Effect of Switching to Azilsartan From Fixed-Dose Combination of an Angiotensin II Receptor Blocker and Calcium Channel Blocker or a Thiazide in Patients With Hypertension.从血管紧张素II受体阻滞剂与钙通道阻滞剂或噻嗪类药物的固定剂量联合用药转换为阿齐沙坦对高血压患者的影响。
J Clin Med Res. 2019 Mar;11(3):202-207. doi: 10.14740/jocmr3723. Epub 2019 Feb 13.
6
[Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].[阿齐沙坦美洛昔酯在高血压合并代谢综合征患者联合治疗中的时效治疗学效率方面]
Kardiologiia. 2016 Oct;56(10):35-40. doi: 10.18565/cardio.2016.10.35-40.
7
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.氢氯噻嗪与氯噻酮联合奥美沙坦酯的降压疗效。
Am J Med. 2012 Dec;125(12):1229.e1-1229.e10. doi: 10.1016/j.amjmed.2012.05.023. Epub 2012 Aug 30.
8
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.新型强效及长效血管紧张素 II 型 1 型受体阻滞剂阿齐沙坦酯在大鼠和犬模型中的降压、胰岛素增敏和肾脏保护作用。
Eur J Pharmacol. 2011 Nov 1;669(1-3):84-93. doi: 10.1016/j.ejphar.2011.07.014. Epub 2011 Jul 28.
9
Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.阿齐沙坦降低慢性肾脏病患者蛋白尿的效果强于坎地沙坦:一项随机交叉试验。
Kidney Blood Press Res. 2021;46(2):173-184. doi: 10.1159/000512365. Epub 2021 Mar 5.
10
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.在 1 期和 2 期高血压患者中,血管紧张素受体阻断剂阿齐沙坦酯与奥美沙坦和缬沙坦对动态血压和诊室血压的影响。
Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31.

本文引用的文献

1
Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.前瞻性比较标准剂量血管紧张素受体阻滞剂和氨氯地平控制不佳的高血压患者中高剂量氨氯地平和吲达帕胺的降压效果和安全性。
Clin Exp Hypertens. 2018;40(2):99-106. doi: 10.1080/10641963.2017.1334798. Epub 2017 Jul 10.
2
A novel cuffless device for self-measurement of blood pressure: concept, performance and clinical validation.一种用于自我测量血压的新型无袖带装置:概念、性能及临床验证。
J Hum Hypertens. 2017 Jul;31(7):479-482. doi: 10.1038/jhh.2016.101. Epub 2017 Jan 26.
3
Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.
使用诊室和动态血压测量评估阿齐沙坦治疗轻至中度高血压患者的疗效
J Clin Hypertens (Greenwich). 2017 Jan;19(1):82-89. doi: 10.1111/jch.12873. Epub 2016 Jul 15.
4
Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.强化与标准血压控制对≥75岁成年人心血管疾病结局的影响:一项随机临床试验。
JAMA. 2016 Jun 28;315(24):2673-82. doi: 10.1001/jama.2016.7050.
5
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.通过家庭血压测量确定的七种血管紧张素II受体阻滞剂的降压作用速度。
J Hypertens. 2016 Jun;34(6):1218-23. doi: 10.1097/HJH.0000000000000902.
6
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的随机试验
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
7
Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study.日本和欧洲高血压患者晨峰血压程度及其决定因素的种族差异:来自ARTEMIS研究的数据。
Hypertension. 2015 Oct;66(4):750-6. doi: 10.1161/HYPERTENSIONAHA.115.05958. Epub 2015 Aug 24.
8
Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease.慢性肾脏病患者血压昼夜变化对心血管事件的种族影响
J Am Soc Hypertens. 2015 Apr;9(4):299-306. doi: 10.1016/j.jash.2015.02.005. Epub 2015 Feb 12.
9
Overcoming the three biases obscuring the science of renal denervation in humans: big-day bias, check-once-more bias and I-will-take-it-now bias.克服阻碍人类肾脏去神经支配科学研究的三种偏见:重大日子偏见、再次检查偏见和我现在就要偏见。
Trends Cardiovasc Med. 2015 Feb;25(2):116-8. doi: 10.1016/j.tcm.2014.10.011. Epub 2014 Oct 31.
10
Updated guidelines for management of high blood pressure in Japan.日本高血压管理的更新指南。
Hypertens Res. 2014 Jun;37(6):484-7. doi: 10.1038/hr.2014.78. Epub 2014 Apr 17.